VBI Vaccines (NASDAQ:VBIV) posted its earnings results on Friday. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.02), MarketWatch Earnings reports. VBI Vaccines had a negative net margin of 6,175.95% and a negative return on equity of 53.12%. The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.24 million.
VBIV stock traded down $0.12 during trading on Friday, hitting $2.05. The stock had a trading volume of 350,317 shares, compared to its average volume of 285,258. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 0.14. VBI Vaccines has a twelve month low of $1.64 and a twelve month high of $5.10.
A number of research firms have recently commented on VBIV. Zacks Investment Research cut VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Wednesday, August 1st. BMO Capital Markets dropped their target price on VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, July 27th. Finally, ValuEngine upgraded VBI Vaccines from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $8.63.
ILLEGAL ACTIVITY NOTICE: “VBI Vaccines (VBIV) Releases Earnings Results, Misses Expectations By $0.02 EPS” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/11/10/vbi-vaccines-vbiv-releases-earnings-results-misses-expectations-by-0-02-eps.html.
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
Read More: Earnings Per Share
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.